Tags

Type your tag names separated by a space and hit enter

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.
J Thromb Thrombolysis. 2020 Apr 03 [Online ahead of print]JT

Abstract

Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 ± 12.0 vs. 58.4 ± 18.0, years, P < 0.001) and with higher platelet count (215 ± 100 vs. 188 ± 98, ×109/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.

Authors+Show Affiliations

Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. tonyjesus@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32246317

Citation

Yin, Shiyu, et al. "Difference of Coagulation Features Between Severe Pneumonia Induced By SARS-CoV2 and Non-SARS-CoV2." Journal of Thrombosis and Thrombolysis, 2020.
Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020.
Yin, S., Huang, M., Li, D., & Tang, N. (2020). Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-020-02105-8
Yin S, et al. Difference of Coagulation Features Between Severe Pneumonia Induced By SARS-CoV2 and Non-SARS-CoV2. J Thromb Thrombolysis. 2020 Apr 3; PubMed PMID: 32246317.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. AU - Yin,Shiyu, AU - Huang,Ming, AU - Li,Dengju, AU - Tang,Ning, Y1 - 2020/04/03/ PY - 2020/4/5/entrez PY - 2020/4/5/pubmed PY - 2020/4/5/medline KW - Coagulopathy KW - Coronavirus disease 2019 KW - D-dimer KW - Severe pneumonia JF - Journal of thrombosis and thrombolysis JO - J. Thromb. Thrombolysis N2 - Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 ± 12.0 vs. 58.4 ± 18.0, years, P < 0.001) and with higher platelet count (215 ± 100 vs. 188 ± 98, ×109/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment. SN - 1573-742X UR - https://www.unboundmedicine.com/medline/citation/32246317/full_citation L2 - https://doi.org/10.1007/s11239-020-02105-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.